Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. develops Alpha DaRT, an intratumoral alpha-radiation therapy being studied for solid tumors. News about DRTS centers on clinical development, regulatory interactions and scientific presentations for Alpha DaRT across oncology programs including recurrent cutaneous squamous cell carcinoma, pancreatic cancer, recurrent glioblastoma, and head and neck cancer.
Company updates frequently cover trial data, feasibility and safety findings, patient enrollment milestones, FDA device-pathway activity, conference abstracts and global study expansion. The news also reflects the company's focus on localized alpha-emitter radiation intended to treat tumors while limiting exposure to surrounding tissue.
On March 28, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) reported its 2021 financial results, highlighting a significant 100% complete response rate in its U.S. pilot trial for skin cancer. The company received two FDA breakthrough device designations and successfully completed its merger with Healthcare Capital Corp, raising approximately $90 million. R&D expenses increased to $11.4 million, resulting in a net loss of $27.3 million for the year. As of December 31, 2021, Alpha Tau's cash reserves stood at $31.9 million, expected to sustain operations for two years.